Výsledky vyhledávání - "Guillén Navarro M"

MELK Inhibition in Diffuse Intrinsic Pontine Glioma

Autor: Meel MH, de Gooijer MC, Guillén Navarro M, Waranecki P, Breur M, Buil L, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Carcaboso AM, Bugiani M, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E

Publikováno v: CLINICAL CANCER RESEARCH
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname

Purpose: Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brain tumor, for which no effective therapeutic options currently exist. We here determined the potential of inhibition of the maternal embryonic leucine zipper kinase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::24b2abc730e58ea575cfc01abada2388
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14709

Zobrazit plný text záznamu

ATRT-05. PRECLINICAL EFFICACY OF RADIATION-FREE TREATMENT OF ATYPICAL TERATOID/RHABDOID TUMORS BY COMBINED MEK AND MELK INHIBITION

Autor: Michaël H. Meel, de Winter M, Esther Hulleman, van Vuurden D, Gertjan L. Kaspers, Guillén-Navarro M, de Gooijer M, Piotr Waranecki

Publikováno v: Neuro-Oncology. 19:iv2-iv2

Atypical teratoid/rhabdoid tumors (AT/RT) are highly malignant tumors that occur both in- and outside the central nervous system, predominantly in young children. Although therapeutic interventions, combining surgery with intensive chemotherapy and c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d79c0a6ef8a4115a8ed653e20f29934
https://doi.org/10.1093/neuonc/nox083.004

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.

Autor: Meel MH; Departments of Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Guillén Navarro M; Departments of Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands., de Gooijer MC; Division of Pharmacology/Mouse Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, Netherlands., Metselaar DS; Departments of Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Waranecki P; Departments of Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Breur M; Department of Pathology, Amsterdam University Medical Centers, Amsterdam, Netherlands., Lagerweij T; Department of Neurosurgery, Neuro-oncology Research Group, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands., Wedekind LE; Department of Neurosurgery, Neuro-oncology Research Group, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands., Koster J; Department of Oncogenomics, Amsterdam University Medical Centers, Amsterdam, Netherlands., van de Wetering MD; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pediatric Oncology, Academic Medical Center, Emma Children's Hospital, Amsterdam, Netherlands., Schouten-van Meeteren N; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pediatric Oncology, Academic Medical Center, Emma Children's Hospital, Amsterdam, Netherlands., Aronica E; Department of (Neuro) Pathology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands., van Tellingen O; Division of Pharmacology/Mouse Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, Netherlands., Bugiani M; Department of Pathology, Amsterdam University Medical Centers, Amsterdam, Netherlands., Phoenix TN; Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati/Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Kaspers GJL; Departments of Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Hulleman E; Departments of Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Publikováno v: Neuro-oncology [Neuro Oncol] 2020 Jan 11; Vol. 22 (1), pp. 58-69.

Zobrazit plný text záznamu

Akademický článek

An Experimenter's Guide to Glioblastoma Invasion Pathways.

Autor: de Gooijer MC; Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; These authors contributed equally to this work., Guillén Navarro M; Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; These authors contributed equally to this work., Bernards R; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Wurdinger T; Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands., van Tellingen O; Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: o.v.tellingen@nki.nl.

Publikováno v: Trends in molecular medicine [Trends Mol Med] 2018 Sep; Vol. 24 (9), pp. 763-780. Date of Electronic Publication: 2018 Jul 30.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání